The Alzheimer’s Disease Neuroimaging Initiative (ADNI) unites researchers with study data as they work to define the progression of Alzheimer’s disease. ADNI researchers collect, validate and utilize data such as MRI and PET images, genetics, cognitive tests, CSF and blood biomarkers as predictors for the disease. Data from the North American ADNI’s study participants, including Alzheimer’s disease patients, mild cognitive impairment subjects and elderly controls, are available from this site.
New UPENN – 2D-UPLC tandem mass spectrometry measurement of Abeta42, Abeta40 and Abeta38 in...
New Metabolomics data provided by the Alzheimer’s Disease Metabolomics Consortium (ADMC- http://sites.duke.edu/adnimetab/) is now available:...